IGX.V - IntelGenx Technologies Corp.

TSXV - TSXV Delayed Price. Currency in CAD

IntelGenx Technologies Corp.

6420 Abrams
Ville Saint-Laurent
Montreal, QC H4S 1Y2
Canada
514-331-7440
http://www.intelgenx.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees32

Key Executives

NameTitlePayExercisedYear Born
Dr. Horst G. ZerbeFounder, Chairman, CEO, Pres & Chairman of Scientific Advisory Board285.75kN/A1947
Mr. Andre Godin CPA, CAExec. VP & CFO247.14kN/A1964
Dr. Dana MatzenVP of Bus. & Corp. Devel.94.99kN/A1978
Ms. Nadine PaiementVice-Chair of Scientific Advisory Board and VP of R&D118.84kN/A1977
Ms. Ingrid ZerbeCo-Founder & Corp. Sec.N/AN/A1954
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

IntelGenx Technologies Corp., a drug delivery company, develops novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company's products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2012 for schizophrenia; and INT0043/2015 to treat cognitive impairment and Alzheimer's disease. It is also developing various products, including INT0037/2013, INT0039/2013, INT0040/2013, INT0042/2015, INT0036/2013, and INT0044/2016 based on three delivery platform technologies, which consist of VersaFilm, an oral film technology; VersaTab, a multilayer tablet technology; and AdVersa, a mucoadhesive tablet technology. The company has co-development and commercialization agreements with RedHill Biopharma Ltd.; Par Pharmaceutical Companies, Inc.; Endo Ventures Ltd., licensing, development, and supply agreement with Chemo Group; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.

Corporate Governance

IntelGenx Technologies Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.